HD Aminos is built around involvement, traceability, and testing—not simply moving boxes. We are not a drop-ship operation that takes an order and leaves the rest to an unknown supplier. We stay closely involved in the sourcing and quality-control process, purchasing in small, carefully managed lots so each lot can receive serious testing and attention.

In an online market where a polished website and a “99% purity” claim can be created overnight, we prefer something more meaningful: know the lot, test the lot, and stand behind the documentation. Bigger catalogs and flashier storefronts are easy. Knowing what you actually have takes considerably more work.

Our products are sourced from a trusted manufacturing partner with rigorous quality systems and consistent production standards. Every batch is then independently tested by a U.S. laboratory, with a Certificate of Analysis (COA) verifying key analytical results for purity and identity.

Our commitment doesn't stop there. We also evaluate our products through our own ongoing research, allowing us to continually assess batch consistency and maintain the high standards we expect before offering products to the research community.

From manufacturing controls to independent verification and internal evaluation, every step reflects our dedication to providing research peptides backed by quality, transparency, and reliability.

Quality. Verified. Trusted.

GLP-3 (R E T A) is an investigational triple-receptor agonist that activates the GLP-1, GIP, and glucagon receptors—three key pathways involved in metabolic regulation. By engaging all three receptors, GLP-3 has become one of the most promising next-generation compounds being studied for its potential to influence appetite signaling, energy expenditure, and overall metabolic function.

Unlike traditional GLP-1 compounds that target a single receptor, GLP-3's unique triple-agonist mechanism is the key difference driving excitement within the research community. Its broader biological approach has made it a leading area of investigation in metabolic and obesity research.

Here's more:

Note: GLP3is still an investigational medication and has not yet been FDA approved. The findings below come from Phase 2 and Phase 3 clinical trials.

• Exceptional Weight Loss

  • Up to 24.2% average body weight loss at 48 weeks in the Phase 2 trial.

  • Phase 3 data reported over 28% average weight loss at 80 weeks, with many participants losing 30% or more of their starting body weight—approaching results typically seen with bariatric surgery.  

  • Source:  ⁠New England Journal of Medicine – Phase 2 Trial

• Improved Blood Sugar Control

  • Significant reductions in HbA1c (average blood glucose) and fasting blood glucose were observed.

  • 72% of participants with prediabetes returned to normal blood sugar levels after 48 weeks in the Phase 2 trial.  

  • Source:  ⁠NEJM Phase 2 Trial

• Reduced Insulin Resistance

  • Participants experienced meaningful reductions in fasting insulin levels, suggesting improved insulin sensitivity and metabolic health.  

  • Source:  ⁠NEJM Phase 2 Trial

• Lower Blood Pressure

  • Both systolic and diastolic blood pressure improved during treatment.

  • Some participants improved enough to reduce or discontinue blood pressure medications.  

  • Source:  ⁠NEJM Phase 2 Trial

• Improved Cholesterol & Blood Lipids

  • Significant improvements were seen in:

    • Triglycerides

    • LDL (“bad”) cholesterol

    • Total cholesterol

    • Other cardiovascular risk markers (HDL changed little).  

  • Source:  ⁠NEJM Phase 2 Trial

• Reduced Waist Circumference

  • Participants lost up to 19.6 cm (7.7 inches) from their waist, indicating substantial reductions in abdominal fat.  

  • Source:  ⁠NEJM Phase 2 Trial

• Quality of Life Improvements

  • Participants reported improvements in several measures of physical functioning and overall quality of life compared with placebo.  

  • Source:  ⁠NEJM Phase 2 Trial

• Muscle Preservation

  • Rapid weight loss with GLP-1–based therapies typically includes some loss of lean body mass. Current retatrutide trials have not demonstrated unique muscle-preserving effects beyond what would be expected with weight loss, and additional studies are ongoing. Claims that it specifically preserves muscle better than other therapies are not yet supported by definitive clinical evidence.  

• Potential Additional Benefits Under Investigation

  • Phase 3 research is evaluating or has reported encouraging findings in:

    • Type 2 diabetes

    • Obstructive sleep apnea

    • Knee osteoarthritis

    • Overall cardiovascular risk reduction

  • These findings are promising but continue to undergo peer review and regulatory evaluation.  

New England Journal of Medicine – Phase 2 Clinical Trial

https://www.nejm.org/doi/full/10.1056/NEJMoa2301972  

PubMed (U.S. National Library of Medicine)

https://pubmed.ncbi.nlm.nih.gov/37366315/  

ClinicalTrials.gov – RTA Studies

https://clinicaltrials.gov/search?term=retatrutide

Reuters – Latest Phase 3 Results

https://www.reuters.com/legal/litigation/lilly-announces-more-next-gen-obesity-drug-data-plans-q1-2027-fda-application-2026-07-23/  

These are among the most authoritative sources available:

• NEJM (peer-reviewed medical journal)

• PubMed (U.S. National Library of Medicine)

• ClinicalTrials.gov (U.S. government clinical trial registry)

• Reuters (reputable news reporting on Phase 3 results)

Primary Reference

• ⁠New England Journal of Medicine – Triple–Hormone-Receptor Agonist RTA for Obesity (Phase 2 Trial)

Additional Reference

• ⁠Reuters – Phase 3 TRIUMPH-1 Results Summary